Literature DB >> 22061175

Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.

W D Shields1, J M Pellock.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22061175     DOI： 10.1111/j.1600-0404.2011.01606.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN： 0065-1427


× No keyword cloud information.
  3 in total

1.  Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues.

Authors:  Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Neurochem Int       Date:  2019-02-26       Impact factor: 3.921

2.  Transcriptome analysis in mice treated with vigabatrin identifies dysregulation of genes associated with retinal signaling circuitry.

Authors:  Dana Walters; Kara R Vogel; Madalyn Brown; Xutong Shi; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Epilepsy Res       Date:  2020-06-20       Impact factor: 3.045

Review 3.  Management of infantile spasms.

Authors:  Gary Rex Nelson
Journal:  Transl Pediatr       Date:  2015-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.